Cowen Downgrades Savient Pharmaceuticals (SVNT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts SVNT Hot Sheet
Price: $40.05 --0%
Rating Summary:
2 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Rating Summary:
2 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 36
Join SI Premium – FREE
Cowen downgraded Savient Pharmaceuticals (NASDAQ: SVNT) to Neutral.
For an analyst ratings summary and ratings history on Savient Pharmaceuticals click here. For more ratings news on Savient Pharmaceuticals click here.
Shares of Savient Pharmaceuticals closed at $2.53 yesterday.
For an analyst ratings summary and ratings history on Savient Pharmaceuticals click here. For more ratings news on Savient Pharmaceuticals click here.
Shares of Savient Pharmaceuticals closed at $2.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Huber Research double downgrades Netflix to underweight, sets $70 price target
- UBS Downgrades Viva Energy Group Ltd. (VEA:AU) to Neutral
- Baird Downgrades Contineum Therapeutics (CTNM) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
